HC Wainwright & Co. Maintains Buy on AcelRx Pharmaceuticals, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on AcelRx Pharmaceuticals (NASDAQ:ACRX) but has lowered the price target from $8 to $5.
September 25, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on AcelRx Pharmaceuticals, indicating continued confidence in the company.
The lowered price target could potentially indicate a perceived decrease in AcelRx's future performance. However, the maintained 'Buy' rating suggests that HC Wainwright & Co. still sees potential in the company, which could balance out any negative impact from the price target adjustment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100